Objective To analyze the incidence of adverse reactions of the third-generation EGFR-TKI aumolertinib,and to provide reference for rational use of the drug in clinic.Methods PubMed,Embase,Web of Science,The Cochrane Library,CNKI,and WanFang Data and SinoMed database were searched to retrieve the literature on post-marketing adverse reactions of aumolertinib that was published from the inception to 16 January 2024 and to perform statistical analyses.Results A total of 12 articles were included in the study,and data on safety was collected from 263 patients.There were 246 adverse reactions caused by ametinib,which were mainly manifested as rash/acne-like rash(17.9%),increased transaminases(12.6%),onychomycosis(7.3%),haematological and lymphatic system disorders(6.1%),and generalized malaise(5.7%).A total of 11 adverse reactions≥grade 3 occurred,and the prognosis was good.Conclusion The adverse reactions of aumolertinib have diverse manifestations,and the effect on the skin and liver function is more obvious.Clinicians are advised to be alert to the occurrence of adverse reactions.
关键词
阿美替尼/表皮生长因子受体-酪氨酸激酶抑制剂/非小细胞肺癌/不良反应/文献分析/合理用药
Key words
aumolertinib/EGFR-TKI/non-small cell lung cancer/adverse reactions/literature analysis/rational drug use
维普
万方数据